The Mouse Phenome Database (MPD) provides access to primary experimental trait data, genotypic variation, protocols and analysis tools for mouse genetic studies. Data are contributed by investigators worldwide and represent a broad scope of phenotyping endpoints and disease-related traits in naïve mice and those exposed to drugs, environmental agents or other treatments. MPD ensures rigorous curation of phenotype data and supporting documentation using relevant ontologies and controlled vocabularies. As a repository of curated and integrated data, MPD provides a means to access/re-use baseline data, as well as allows users to identify sensitized backgrounds for making new mouse models with genome editing technologies, analyze trait co-inheritance, benchmark assays in their own laboratories, and many other research applications. MPD’s primary source of funding is NIDA. For this reason, a majority of MPD data is neuro- and behavior-related.
GeneWeaver is a web application for the integrated cross-species analysis of functional genomics data to find convergent evidence from heterogeneous sources. The application consists of a large database of gene sets curated from multiple public data resources and curated submissions, along with a suite of analysis tools designed to allow flexible, customized workflows through web-based interactive analysis or scripted API driven analysis. Gene sets come from multiple widely studied species and include ontology annotations, brain gene expression atlases, systems genetic study results, gene regulatory information, pathway databases, drug interaction databases and many other sources. Users can retrieve, store, analyze and share gene sets through a graded access system. Analysis tools are based on combinatorics and statistical methods for comparing, contrasting, and classifying gene sets based on their members.
GeneWeaver is a web application for the integrated cross-species analysis of functional genomics data to find convergent evidence from heterogeneous sources. The application consists of a large database of gene sets curated from multiple public data resources and curated submissions, along with a suite of analysis tools designed to allow flexible, customized workflows through web-based interactive analysis or scripted API driven analysis. Gene sets come from multiple widely studied species and include ontology annotations, brain gene expression atlases, systems genetic study results, gene regulatory information, pathway databases, drug interaction databases and many other sources. Users can retrieve, store, analyze and share gene sets through a graded access system. Analysis tools are based on combinatorics and statistical methods for comparing, contrasting and classifying gene sets based on their members.
Longitudinal Online Research and Imaging System (LORIS) is a web-based data and project management software for neuroimaging research studies. It is an open source framework for storing and processing behavioural, clinical, neuroimaging and genetic data. LORIS also makes it easy to manage large datasets acquired over time in a longitudinal study, or at different locations in a large multi-site study.
This talk highlights a set of platform technologies, software, and data collections that close and shorten the feedback cycle in research.
An agent for reproducible neuroimaging
The Identifiers.org system is a central infrastructure for findable, accessible, interoperable and re-usable (FAIR) data. It provides a range of services to generate, resolve and validate persistent Compact Identifiers to promote the citability of individual data providers and integration with e-infrastructures.
This lecture provides an overview of depression (epidemiology and course of the disorder), clinical presentation, somatic co-morbidity, and treatment options.
This lecture will highlight our current understanding and recent developments in the field of neurodegenerative disease research, as well as the future of diagnostics and treatment of neurodegenerative diseases
An overview of some of the essential concepts in neuropharmacology (e.g. receptor binding, agonism, antagonism), an introduction to pharmacodynamics and pharmacokinetics, and an overview of the drug discovery process relative to diseases of the Central Nervous System.
Neuroethics has been described as containing at least two components - the neuroscience of ethics and the ethics of neuroscience. The first involves neuroscientific theories, research, and neuro-imaging focused on how the brain arrives at moral decisions and actions, which challenge existing descriptive theories of how humans develop moral thinking and make ethical decisions. The second, ethics of neuroscience, involves applying normative theories about what is right, good and fair to ethical questions raised by neuroscientific research and new technologies, such as how to balance the public benefit of “big data” neuroscience while protecting individual privacy and norms of informed consent.
The HBP as an ICT flagship project crucially relies on ICT and will contribute important input into the development of new computing principles and artefacts. Individuals working on the HBP should therefore be aware of the long history of ethical issues discussed in computing. The discourse on ethics and computing can be traced back to Norbert Wiener and the very beginning of digital computing. From the 1970s and 80s it has developed into an active discussion involving academics from various disciplines, professional bodies and industry.
Like any transformative technology, intelligent robotics has the potential for huge benefit, but is not without ethical or societal risk. In this lecture, I will explore two questions. Firstly, the increasingly urgent question of the ethical use of robots: are there particular applications of robots that should be proscribed, in eldercare, or surveillance, or war fighting for example? When intelligent autonomous robots make mistakes, as they inevitably will, who should be held to account? Secondly, I will consider the longer-term question of whether intelligent robots themselves could or should be ethical. Seventy years ago Isaac Asimov created his fictional Three Laws of Robotics. Is there now a realistic prospect that we could build a robot that is Three Laws Safe?
In the face of perceived public concerns about technological innovations, leading national and international bodies increasingly argue that there must be ‘dialogue' between policy makers, scientific researchers, civil society organizations and members of the public, to shape the pathways of technology development in a way that meets societal needs and gains public trust. This is not new, of course, and such concerns go back at least to the debates over the development of nuclear technologies and campaigns for social responsibility in science. Major funding bodies in the UK, Europe and elsewhere are now addressing this issue by insisting on Responsible Research and Innovation (RRI) in the development of emerging technology. Biotechnologies such as synthetic biology and neurotechnologies have become a particular focus of RRI, partly because of the belief that these are risky technologies involving tinkering with the very building blocks of life, and perhaps even with human nature. With my fellow researchers, I have been involved in trying to develop Responsible Research and Innovation in these technologies for several years.
In this lecture, I consider some of the key social and ethical issues raised by the ‘big brain projects’ currently under way in Europe, the USA, China, Japan and many other regions. I will draw upon our own experience in the ‘ Foresight Lab’ of the HBP to discuss the ways in which these can usefully be approached from the perspective of responsible research and innovation and the AREA approach - anticipation, reflection, engagement and action. These include data protection, privacy and data governance; the search for ‘neural signatures’ of psychaitric and neurological disorders; ‘dual use’ or the military use of developments initially intended for clinical and civilian purposes; brain-computer interfaces and neural prosthetics; and the use of animals in brain research. Following a brief discussion of the challenges of translation from the lab to the real world, I will conclude by arguing that success in contemporary scientific research and innovation is best assured by openness, collaboration, sharing with fellow researchers; robust systems of data governance involving lay persons; frankness about realities of scientific research and innovation with fellow citizens; realism about complexities of links between researchers, publics and private enterprise; and understanding and engaging with the realities of science today in the real world.